Guggenheim raised the firm’s price target on Natera (NTRA) to $270 from $230 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $285 from $260 at Canaccord
- Natera publishes findings from CALGB/SWOG 80702 study in JAMA Oncology
- NeoGenomics announce Natera withdrawal of appeal in patent litigation
- Natera price target raised to $260 from $250 at JPMorgan
- Natera price target raised to $205 from $190 at Wells Fargo